Frontiers in Oncology (Mar 2024)
CD20+ T cells in monoclonal B cell lymphocytosis and chronic lymphocytic leukemia: frequency, phenotype and association with disease progression
- Cristiana Rodrigues,
- Cristiana Rodrigues,
- Paula Laranjeira,
- Paula Laranjeira,
- Paula Laranjeira,
- Paula Laranjeira,
- Paula Laranjeira,
- Aryane Pinho,
- Aryane Pinho,
- Aryane Pinho,
- Isabel Silva,
- Sandra Silva,
- Margarida Coucelo,
- Ana Catarina Oliveira,
- Ana Teresa Simões,
- Inês Damásio,
- Helena Matos Silva,
- Mafalda Urbano,
- Ana Bela Sarmento-Ribeiro,
- Ana Bela Sarmento-Ribeiro,
- Ana Bela Sarmento-Ribeiro,
- Ana Bela Sarmento-Ribeiro,
- Ana Bela Sarmento-Ribeiro,
- Catarina Geraldes,
- Catarina Geraldes,
- Catarina Geraldes,
- Catarina Geraldes,
- Catarina Geraldes,
- M. Rosário Domingues,
- M. Rosário Domingues,
- Julia Almeida,
- Julia Almeida,
- Julia Almeida,
- Julia Almeida,
- Ignacio Criado,
- Ignacio Criado,
- Ignacio Criado,
- Ignacio Criado,
- Alberto Orfao,
- Alberto Orfao,
- Alberto Orfao,
- Alberto Orfao,
- Artur Paiva,
- Artur Paiva,
- Artur Paiva,
- Artur Paiva,
- Artur Paiva
Affiliations
- Cristiana Rodrigues
- Flow Cytometry Unit, Department of Clinical Pathology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
- Cristiana Rodrigues
- Department of Chemistry, University of Aveiro, Aveiro, Portugal
- Paula Laranjeira
- Flow Cytometry Unit, Department of Clinical Pathology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
- Paula Laranjeira
- Coimbra Institute for Clinical and Biomedical Research (iCBR), Group of Environmental Genetics of Oncobiology (CIMAGO), Faculty of Medicine (FMUC), University of Coimbra, Coimbra, Portugal
- Paula Laranjeira
- Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Portugal
- Paula Laranjeira
- Clinical Academic Center of Coimbra (CACC), Coimbra, Portugal
- Paula Laranjeira
- Center for Neuroscience and Cell Biology (CNC), University of Coimbra, Coimbra, Portugal
- Aryane Pinho
- Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Portugal
- Aryane Pinho
- Center for Neuroscience and Cell Biology (CNC), University of Coimbra, Coimbra, Portugal
- Aryane Pinho
- Department of Life Sciences, Faculty of Sciences and Technology, University of Coimbra, Coimbra, Portugal
- Isabel Silva
- Flow Cytometry Unit, Department of Clinical Pathology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
- Sandra Silva
- Flow Cytometry Unit, Department of Clinical Pathology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
- Margarida Coucelo
- Unidade Funcional de Hematologia Molecular, Serviço de Hematologia Clínica, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
- Ana Catarina Oliveira
- Unidade Funcional de Hematologia Molecular, Serviço de Hematologia Clínica, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
- Ana Teresa Simões
- Unidade Funcional de Hematologia Molecular, Serviço de Hematologia Clínica, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
- Inês Damásio
- Hematology Department, Centro Hospitalar Tondela-Viseu, Viseu, Portugal
- Helena Matos Silva
- Hematology Department, Centro Hospitalar Tondela-Viseu, Viseu, Portugal
- Mafalda Urbano
- 0Hematology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
- Ana Bela Sarmento-Ribeiro
- Coimbra Institute for Clinical and Biomedical Research (iCBR), Group of Environmental Genetics of Oncobiology (CIMAGO), Faculty of Medicine (FMUC), University of Coimbra, Coimbra, Portugal
- Ana Bela Sarmento-Ribeiro
- Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Portugal
- Ana Bela Sarmento-Ribeiro
- Clinical Academic Center of Coimbra (CACC), Coimbra, Portugal
- Ana Bela Sarmento-Ribeiro
- 0Hematology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
- Ana Bela Sarmento-Ribeiro
- 1University Clinics of Hematology and Oncology and Laboratory of Oncobiology and Hematology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal
- Catarina Geraldes
- Coimbra Institute for Clinical and Biomedical Research (iCBR), Group of Environmental Genetics of Oncobiology (CIMAGO), Faculty of Medicine (FMUC), University of Coimbra, Coimbra, Portugal
- Catarina Geraldes
- Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Portugal
- Catarina Geraldes
- Clinical Academic Center of Coimbra (CACC), Coimbra, Portugal
- Catarina Geraldes
- 0Hematology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
- Catarina Geraldes
- 1University Clinics of Hematology and Oncology and Laboratory of Oncobiology and Hematology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal
- M. Rosário Domingues
- 2Mass Spectrometry Centre, Associated Laboratory for Green Chemistry (LAQV-REQUIMTE), Department of Chemistry, University of Aveiro, Aveiro, Portugal
- M. Rosário Domingues
- 3CESAM—Centre for Environmental and Marine Studies, Department of Chemistry, University of Aveiro, Aveiro, Portugal
- Julia Almeida
- 4Translational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC-University of Salamanca), Salamanca, Spain
- Julia Almeida
- 5Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain
- Julia Almeida
- 6Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain
- Julia Almeida
- 7Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
- Ignacio Criado
- 4Translational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC-University of Salamanca), Salamanca, Spain
- Ignacio Criado
- 5Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain
- Ignacio Criado
- 6Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain
- Ignacio Criado
- 7Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
- Alberto Orfao
- 4Translational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC-University of Salamanca), Salamanca, Spain
- Alberto Orfao
- 5Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain
- Alberto Orfao
- 6Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain
- Alberto Orfao
- 7Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
- Artur Paiva
- Flow Cytometry Unit, Department of Clinical Pathology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
- Artur Paiva
- Coimbra Institute for Clinical and Biomedical Research (iCBR), Group of Environmental Genetics of Oncobiology (CIMAGO), Faculty of Medicine (FMUC), University of Coimbra, Coimbra, Portugal
- Artur Paiva
- Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Portugal
- Artur Paiva
- Clinical Academic Center of Coimbra (CACC), Coimbra, Portugal
- Artur Paiva
- 8Ciências Biomédicas Laboratoriais, Instituto Politécnico de Coimbra, Escola Superior de Tecnologia da Saúde de Coimbra (ESTESC)-Coimbra Health School, Coimbra, Portugal
- DOI
- https://doi.org/10.3389/fonc.2024.1380648
- Journal volume & issue
-
Vol. 14
Abstract
IntroductionIn monoclonal B cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL), the expansion of malignant B cells disrupts the normal homeostasis and interactions between B cells and T cells, leading to immune dysregulation. CD20+ T cells are a subpopulation of T cells that appear to be involved in autoimmune diseases and cancer.MethodsHere, we quantified and phenotypically characterized CD20+ T cells from MBL subjects and CLL patients using flow cytometry and correlated our findings with the B-cell receptor mutational status and other features of the disease. Results and discussionCD20+ T cells were more represented within the CD8+ T cell compartment and they showed a predominant memory Tc1 phenotype. CD20+ T cells were less represented in MBL and CLL patients vs healthy controls, particularly among those with unmutated IGVH gene. The expansion of malignant B cells was accompanied by phenotypic and functional changes in CD20+ T cells, including an increase in follicular helper CD4+ CD20+ T cells and CD20+ Tc1 cells, in addition to the expansion of the TCR Vβ 5.1 in CD4+ CD20+ T cells in CLL.
Keywords
- CD20+ T cells
- chronic lymphocytic leukemia
- monoclonal B lymphocytosis
- immunoglobulin heavy chain variable region
- T cell polarization
